DONNELLY HOWARD W
Known title: DirectorCIK: 0001212978
Associated companies
Transaction History
| ANGO | ▲ Buy | Grant | 11,887 | $0 | 7/15/2026 | View on chart |
| ANGO | ▲ Buy | Grant | 17,675 | $0 | 7/16/2025 | View on chart |
| ANGO | ▲ Buy | Grant | 20,541 | $0 | 7/17/2024 | View on chart |
| ANGO | ▲ Buy | Grant | 17,041 | $0 | 7/19/2023 | View on chart |
| ANGO | ▲ Buy | Grant | 7,060 | $0 | 7/20/2022 | View on chart |
| ANGO | ▲ Buy | Option Exercise | 6,022 | $96K | 4/20/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ANGO Announces Q1 Fiscal 2027 Results Date
AngioDynamics (ANGO) will report its fiscal 2027 first‑quarter earnings on Oct. 8, 2026. The earnings release will provide updated guidance on revenue, operating income and cash flow for the quarter. Analysts will review the results to assess the company’s performance against expectations. The announcement is the main event for the stock this week.
ANGO Announces Q1 Fiscal 2027 Results Date. AngioDynamics (ANGO) will report its fiscal 2027 first‑quarter earnings on Oct. 8, 2026. The earnings release will provide updated guidance on revenue, operating income and cash flow for the quarter. Analysts will review the results to assess the company’s performance against expectations. The announcement is the main event for the stock this week.